Skip to search formSkip to main contentSkip to account menu

Talsaclidine

Known as: (3R)-3-(2-Propynyloxy)quinuclidine 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Development and Validation of Chiral HPLC Method for Quantification of 3-(S)-Quinuclidinol in Pharmaceutically Important Precursor, 3-(R)-Quinuclidinol, by Precolumn Derivatization.
A sensitive and specific high-performance liquid chromatography (HPLC) method for the separation and quantification of 3-(S… 
Highly Cited
2004
Highly Cited
2004
Beta‐secretase BACE1 is differentially controlled through muscarinic acetylcholine receptor signaling
The β‐amyloid peptides derived by proteolytic cleavage from the amyloid precursor protein (APP) play a major role in the… 
Highly Cited
2003
Highly Cited
2003
Treatment with the selective muscarinic ml agonist talsaclidine decreases cerebrospinal fluid levels of Aβ42 in patients with Alzheimer's disease
The amyloid p-peptides Aβ40 and Aβ42 are highly amyloidogenic constituents of brain Pamyloid plaques in Alzheimer's disease (AD… 
2002
2002
Memory-related task performance by aged rhesus monkeys administered the muscarinic M1-preferring agonist, talsaclidine
HeadingAbstractRationale. Muscarinic-acetylcholine receptor agonists are yet to be used clinically for the treatment of Alzheimer… 
2002
2002
A 12-week clinical trial of talsaclidine, a muscarinic agonist, in the treatment of mild to moderate Alzheimer's disease
2001
2001
Pharmacodynamic profile of the M1 agonist talsaclidine in animals and man.
2001
2001
Drugs for the Treatment of Alzheimer's Disease
Alzheimer’ disease (AD) is a progressive neurodegenerative cerebral disorder mostly incident in presenile and senile age, which… 
1998
1998
Central activation of the sympathetic nervous system including the adrenals in anaesthetized guinea pigs by the muscarinic agonist talsaclidine
Talsaclidine, a novel M1-receptor selective muscarinic agonist for cholinergic substitution therapy of Alzheimer’s disease… 
1997
1997
Compensation of muscarinic bronchial effects of talsaclidine by concomitant sympathetic activation in guinea pigs.
1997
1997
In vivo consequences of M1-receptor activation by talsaclidine.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)